Stock Events

Arrowhead Pharmaceuticals 

R$12.89
54
+R$0+0% Today

Statistics

Day High
13.34
Day Low
12.89
52W High
23.51
52W Low
12.18
Volume
57
Avg. Volume
375
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.92
-1.13
-0.34
0.45
Expected EPS
-0.937127
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow A2RR34.SA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals is a direct competitor in the RNA interference (RNAi) therapeutic space, targeting similar diseases as Arrowhead.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals competes in the development of RNA-targeted therapies, sharing a focus on genetic and rare diseases.
Moderna
MRNA
Mkt Cap29.75B
Moderna is involved in mRNA therapeutics and vaccines, representing competition in the broader RNA-based treatment market.
BioNTech
BNTX
Mkt Cap20.98B
BioNTech competes in the mRNA space, particularly in vaccines, but its technology could extend into therapeutic areas overlapping with Arrowhead's interests.
Sarepta Therapeutics
SRPT
Mkt Cap12.95B
Sarepta Therapeutics focuses on RNA-targeted treatments, especially for rare diseases, competing in the genetic medicine field alongside Arrowhead.
Regulus Therapeutics
RGLS
Mkt Cap109.98M
Regulus Therapeutics is involved in developing treatments targeting microRNAs, a form of RNA therapy that could compete with Arrowhead's RNAi products.
Arcturus Therapeutics
ARCT
Mkt Cap570.59M
Arcturus Therapeutics works on mRNA medicines for various diseases, including those in Arrowhead's target areas, making them competitors in RNA-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is focused on gene editing, a different but related approach to treating diseases at the genetic level, potentially competing for similar therapeutic indications.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another company working on CRISPR-based gene editing, competing in the genetic medicine space where RNA therapies like Arrowhead's are also relevant.

About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Show more...
CEO
Dr. Christopher R. Anzalone Ph.D.
Employees
397
Country
United States
ISIN
BRA2RRBDR009

Listings